A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a new medication called vamorolone is safe
and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and < 7 years old.
Phase:
Phase 2
Details
Lead Sponsor:
ReveraGen BioPharma, Inc.
Collaborators:
Cooperative International Neuromuscular Research Group National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) National Institute of Neurological Disorders and Stroke (NINDS) University of Pittsburgh